NCT07115563 Daily Amino Acid Supplementation for People With Parkinson's Disease
| NCT ID | NCT07115563 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cristina Colon-Semenza |
| Condition | Parkinson Disease (PD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-10-31 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-10-31 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if a tailored amino acid supplement works to help adults living with Parkinson's disease to improve nutrition, metabolic function, body composition, and physical and mental function. The main questions it aims to answer are: Does the tailored amino acid supplement increase essential amino acids (nutritional status)? Does the tailored amino acid supplement increase an antioxidant (complex amino acid) and decrease an amino acid associated with oxidative stress? Does the tailored amino acid supplement improve physical and mental health compared to a placebo supplement? Researchers will compare the tailored amino acid supplement to a placebo (a look-alike substance that contains no active ingredients) to see if the tailored amino acid supplements work to support health for people with Parkinson's disease. Participants will: Take the tailored amino acid supplement or a placebo every day for 6 months, visit the lab at baseline, after 3 months, and after 6 months for fasting blood draws, body composition assessment, and physical and mental health testing and keep a diary of their food intake and supplement intake.
Eligibility Criteria
Inclusionary Criteria: * Male and Females. * 60-80 Years. * Previous diagnosis of idiopathic Parkinson's Disease by patient report. * Use of dopamine replacement medication (e.g. levodopa) for at least 2 years. * On a stable dose of dopamine replacement medication for at least 3 months with no plans for change in the next two months. Exclusionary criteria * Apparent cognitive impairment as determined by phone screening (Telephone Interview for Cognitive Status \<29). * Diagnosis of Parkinsonism or atypical Parkinson's Disease. * Prescription of Dopamine antagonist. * Any unstable medical condition. * Any known bleeding disorder or current consumption of blood thinners. * Use of Deep Brain Stimulation. * Gastric or Bowel resection surgery. * Contraindications to blood draw.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07115563 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 80 Years, studying Parkinson Disease (PD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07115563 currently recruiting?
Yes, NCT07115563 is actively recruiting participants. Contact the research team at carlos.rehbein@uconn.edu for enrollment information.
Where is the NCT07115563 trial being conducted?
This trial is being conducted at Storrs, United States.
Who is sponsoring the NCT07115563 clinical trial?
NCT07115563 is sponsored by Cristina Colon-Semenza. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.